UBX - ユニティ―・バイオテクノロジ― (Unity Biotechnology Inc.)


   H.C. Wainwright Thinks Unity Biotechnologys Stock is Going to Recover  2021/06/07 10:29:33 Smarter Analyst
In a report released today, Andrew Fein from H.C. The post H.C. Wainwright Thinks Unity Biotechnologys Stock is Going to Recover appeared first on Smarter Analyst .
   Unity Biotechnology Consensus Indicates Potential 29.6% Upside  2021/06/06 16:16:33 DirectorsTalk
Unity Biotechnology found using ticker (UBX) have now 6 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The range between the high target price and low target price is between 12 and 4 with the average target price sitting at 6. Now with the previous closing price of 4.63 this indicates there is a potential upside of 29.6%. The day 50 moving average is 4.68 and the 200 moving average now moves to 5.95. The market capitalisation for the company is $250m. Visit the company website at: /> [stock_market_widget type="chart" symbol="UBX" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Unity Biotechnology, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company''s lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
   Anti-Senescence Therapy Market to Witness Huge Growth by 2028 | Unity Biotechnology, Siwa Therapeutics, Calico LLC  2021/05/25 18:04:34 Jumbo News
Global Anti-Senescence Therapy Market Report is an objective and in-depth study of the current state aimed at the major drivers, market strategies, and key players growth. The study also involves the important Achievements of the market, Research & Development, new product launch, product responses and regional growth of the leading competitors operating in the market on []
   Anti-Ageing Drugs Market to Eyewitness Massive Growth by 2026 | Frequency Therapeutics, Nuritas, Unity Biotechnology, Elysium  2021/05/14 13:52:15 OpenPR
The Latest survey report on Anti-Ageing Drugs Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Anti-Ageing Drugs organizations have the dual challenge of increasing interoperability to improve clinical performance
   UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates  2021/05/11 12:00:00 GlobeNewswire
- UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity
   Unity Biotechnology Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/16 17:44:00 Stock Market Daily
Unity Biotechnology announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs  2020/08/19 11:32:33 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) DarioHealth Corp (NASDAQ: DRIO ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Otonomy Inc (NASDAQ: OTIC ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Pacira Biosciences Inc (NASDAQ: PCRX ) PDL BioPharma Inc (NASDAQ: PDLI ) Principia Biopharma Inc (NASDAQ: PRNB ) Qiagen NV (NYSE: QGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Syros Pharmaceuticals Inc (NASDAQ: SYRS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Interpace Biosciences Inc (NASDAQ: IDXG )(announced receipt of letters from recently departed employees regarding billing and compliance issues) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Poseida Therapeutics, Inc. (NASDAQ: PSTX )( announced clinical hold on its Phase 1 prostate cancer study) Predictive Oncology Inc (NASDAQ: POAI ) Recro Pharma Inc (NASDAQ: REPH ) Unity Biotechnology Inc (NASDAQ: UBX ) Stocks In Focus Venrock Reports Purchase of 451K Unum Shares Unum Therapeutics Inc (NASDAQ: UMRX ) shares advanced after Venrock Healthcare Partners III L.P. said in a filing it has purchased 451,000 shares of Unum's common stock in a series of transactions effected between Aug. 14 and Aug. 18, bringing the total number of shares owned by the fund to 4.355 million The stock climbed 16.24% to $3.15 in after-hours trading.
   Barrick Gold : Thinking about buying stock in Immatics NV, Biocept Inc, LMP Automotive, Unity Biotechnology, or Barrick Gold Corp? | MarketScreener  2020/08/18 13:32:06 MarketScreener
NEW YORK, Aug. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMTX, BIOC, LMPX, UBX, and GOLD. … | August 18, 2020
   Unity Biotech Craters After Lead Drug Flunks Midstage Osteoarthritis Study  2020/08/17 18:38:57 Benzinga
Shares of Unity Biotechnology Inc (NASDAQ: UBX ), which went public in mid-2018, were moving notably lower Monday following an adverse clinical readout. What Happened: San Francisco, California-based Unity said the 12-week results from the Phase 2 study of its lead asset UBX0101 showed that the trial did not meet the primary endpoint. The study looked at the p53/MDM2 interaction inhibitor in patients with moderate-to-severe painful osteoarthritis of the knee. "There was no … Full story available on Benzinga.com